For Healthcare Professionals

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors


About the study

The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
  2. In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
  3. Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  4. Adequate organ function, including hematologic, hepatic, and renal.
  5. Estimated life expectancy of ≥12 weeks.


Exclusion Criteria:

  1. Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
  2. Have serious preexisting medical conditions.
  3. Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
  4. Have an active bacterial, fungal, and/or known viral infection.
  5. Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Advanced Solid Tumor

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Oct 31, 2023

Treatment type



Eli Lilly and Company identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.